C Michael Foley
Overview
Explore the profile of C Michael Foley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
223
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pugsley M, Winters B, Koshman Y, Authier S, Foley C, Hayes E, et al.
J Pharmacol Toxicol Methods
. 2024 Jun;
128:107533.
PMID: 38945308
This editorial prefaces the annual themed issue on safety pharmacology (SP) methods which has been published since 2004 in the Journal of Pharmacological and Toxicological Methods (JPTM). Here we highlight...
2.
Wisialowski T, Ether N, Foley C, Kleiman R, Koshman Y, Leishman D, et al.
J Pharmacol Toxicol Methods
. 2024 May;
128:107515.
PMID: 38777240
No abstract available.
3.
De Alwis D, Foley C, Herman E, Hill A, Hoffmann P, Kanda Y, et al.
J Pharmacol Toxicol Methods
. 2024 Apr;
127:107507.
PMID: 38636673
The Health and Environmental Sciences Institute (HESI) Cardiac Safety Committee designed and created a publicly accessible database with an initial set of 128 pharmacologically defined pharmaceutical agents, many with known...
4.
Antic O, Koshman Y, Bird B, Jasiek G, Wilsey A, Mittelstadt S, et al.
J Pharmacol Toxicol Methods
. 2024 Mar;
126:107497.
PMID: 38479593
The strategic and targeted use of an anesthetized canine cardiovascular model early in drug discovery enables a comprehensive cardiovascular and electrophysiological assessment of potential safety liabilities and guides compound selection...
5.
Koshman Y, Kohnken R, Logan M, Mittelstadt S, Foley C
Toxicol Sci
. 2024 Jan;
198(2):316-327.
PMID: 38191231
Cardiovascular toxicity is one of the more common causes of attrition in preclinical and clinical drug development. Preclinical cardiovascular safety assessment involves numerous in vitro and in vivo endpoints which...
6.
Pugsley M, Koshman Y, Foley C, Winters B, Authier S, Curtis M
J Pharmacol Toxicol Methods
. 2023 Jul;
123:107300.
PMID: 37524151
This editorial prefaces the annual themed issue on safety pharmacology (SP) methods published since 2004 in the Journal of Pharmacological and Toxicological Methods (JPTM). We highlight here the content derived...
7.
Ross R, Foley C, Jones H, Osinski M
J Pharmacol Toxicol Methods
. 2022 Jun;
116:107189.
PMID: 35688321
Cardiovascular safety is a key area of concern for new drugs in development, and the collection and analysis of electrocardiograms (ECGs) is a standard and major component of nonclinical testing....
8.
Koshman Y, Wilsey A, Bird B, Sadilek S, Weisbecker D, Ebert P, et al.
J Pharmacol Toxicol Methods
. 2021 Aug;
111:107109.
PMID: 34416395
Introduction: A successful integration of automated blood sampling (ABS) into the telemetry instrumented canine cardiovascular model is presented in this study. This combined model provides an efficient means to quickly...
9.
Koshman Y, Lai-Zhang J, Wilsey A, Bird B, Sadilek S, Weisbecker D, et al.
J Pharmacol Toxicol Methods
. 2021 Aug;
112:107115.
PMID: 34403748
Introduction: This manuscript presents a successful integration of multi-timepoint biomarker blood sampling (e.g., cytokines) in a conscious dog cardiovascular study using automated blood sampling via vascular access ports in telemetry...
10.
Koshman Y, Wilsey A, Bird B, Sadilek S, Weisbecker D, Ebert P, et al.
J Pharmacol Toxicol Methods
. 2021 Apr;
109:107066.
PMID: 33838254
Introduction: A successful integration of automated blood sampling (ABS) into the telemetry instrumented canine cardiovascular model is presented in this study. This combined model provides an efficient means to quickly...